Cargando…
DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2
As per date, around 20 million COVID-19 cases reported from across the globe due to a tiny 125 nm sized virus: SARS-CoV-2 which has created a pandemic and left an unforgettable impact on our world. Besides vaccine, medical community is in a race to identify an effective drug, which can fight against...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342190/ https://www.ncbi.nlm.nih.gov/pubmed/34376872 http://dx.doi.org/10.1016/j.molstruc.2021.131253 |
_version_ | 1783734016593100800 |
---|---|
author | Yadav, Pooja Rana, Meenakshi Chowdhury, Papia |
author_facet | Yadav, Pooja Rana, Meenakshi Chowdhury, Papia |
author_sort | Yadav, Pooja |
collection | PubMed |
description | As per date, around 20 million COVID-19 cases reported from across the globe due to a tiny 125 nm sized virus: SARS-CoV-2 which has created a pandemic and left an unforgettable impact on our world. Besides vaccine, medical community is in a race to identify an effective drug, which can fight against this disease effectively. Favipiravir (F) has recently attracted too much attention as an effective repurposed drug against COVID-19. In the present study, the pertinency of F has been tested as an antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 with the help of density functional theory (DFT) and MD Simulation. Different electronic properties of F such as atomic charges, molecular electrostatic properties (MEP), chemical reactivity and absorption analysis have been studied by DFT. In order to understand the interaction and stability of inhibitor F against viral protease, molecular docking and MD simulation have been performed. Various output like interaction energies, number of intermolecular hydrogen bonding, binding energy etc. have established the elucidate role of F for the management of CoV-2 virus for which there is no approved therapies till now. Our findings highlighted the need to further evaluate F as a potential antiviral against SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8342190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83421902021-08-06 DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 Yadav, Pooja Rana, Meenakshi Chowdhury, Papia J Mol Struct Article As per date, around 20 million COVID-19 cases reported from across the globe due to a tiny 125 nm sized virus: SARS-CoV-2 which has created a pandemic and left an unforgettable impact on our world. Besides vaccine, medical community is in a race to identify an effective drug, which can fight against this disease effectively. Favipiravir (F) has recently attracted too much attention as an effective repurposed drug against COVID-19. In the present study, the pertinency of F has been tested as an antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 with the help of density functional theory (DFT) and MD Simulation. Different electronic properties of F such as atomic charges, molecular electrostatic properties (MEP), chemical reactivity and absorption analysis have been studied by DFT. In order to understand the interaction and stability of inhibitor F against viral protease, molecular docking and MD simulation have been performed. Various output like interaction energies, number of intermolecular hydrogen bonding, binding energy etc. have established the elucidate role of F for the management of CoV-2 virus for which there is no approved therapies till now. Our findings highlighted the need to further evaluate F as a potential antiviral against SARS-CoV-2. Elsevier B.V. 2021-12-15 2021-08-06 /pmc/articles/PMC8342190/ /pubmed/34376872 http://dx.doi.org/10.1016/j.molstruc.2021.131253 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Yadav, Pooja Rana, Meenakshi Chowdhury, Papia DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 |
title | DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 |
title_full | DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 |
title_fullStr | DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 |
title_full_unstemmed | DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 |
title_short | DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2 |
title_sort | dft and md simulation investigation of favipiravir as an emerging antiviral option against viral protease (3cl(pro)) of sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342190/ https://www.ncbi.nlm.nih.gov/pubmed/34376872 http://dx.doi.org/10.1016/j.molstruc.2021.131253 |
work_keys_str_mv | AT yadavpooja dftandmdsimulationinvestigationoffavipiravirasanemergingantiviraloptionagainstviralprotease3clproofsarscov2 AT ranameenakshi dftandmdsimulationinvestigationoffavipiravirasanemergingantiviraloptionagainstviralprotease3clproofsarscov2 AT chowdhurypapia dftandmdsimulationinvestigationoffavipiravirasanemergingantiviraloptionagainstviralprotease3clproofsarscov2 |